# US 11,077,180 B2 · Non-lipidated variants of Neisseria meningitidis ORF2086 antigens

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,077,180 B2
- Document ID: US11077180B2
- Status: Granted
- Kind: B2
- Application number: 16/598,661
- Filed: 2019-10-10
- Published: 2020-03-26
- Granted: 2021-08-03
- Earliest claimed: 2010-09-10
- Assignees: Wyeth
- Applicants: Wyeth LLC
- Inventors: Annaliesa Sybil Anderson; Kathrin Ute Jansen; Mark Edward Ruppen; Justin Keith Moran; Susan Kay Hoiseth
- Web page: https://patentgrep.com/patent/US11077180B2

## CPC

- A61K 39/095: Neisseria
- A61P 31/04: Antibacterial agents
- A61P 37/04: Immunostimulants
- C07K 14/22: from Neisseriaceae (F)
- C07K 16/1217: Neisseriaceae (F)
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/55577: {Saponins; Quil A; QS21; ISCOMS}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to compositions including an isolated non-pyruvylated non-lipidated ORF2086 polypeptide, and methods thereof. In an exemplary embodiment, the compositions described herein are immunogenic. The present invention further relates to compositions that elicit a bactericidal immune response in a mammal against an ORF2086 subfamily B polypeptide from serogroup B Neisseria meningitidis, and methods related thereto.

## Claims

### Claim 1

A method of eliciting an immune response against Neisseria meningitidis serogroup B, subfamily B, in a mammal, comprising administering to the mammal an immunogenic composition comprising an immunologically effective amount of a first non-pyruvylated non-lipidated polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 19, wherein the first non-pyruvylated non-lipidated polypeptide lacks cysteine at the N-terminus of SEQ ID NO: 19 and does not exhibit a mass shift of +70 Da compared to the corresponding wild-type non-lipidated polypeptide as measured by mass spectrometry.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said immunogenic composition further comprises an immunologically effective amount of a second non-pyruvylated non-lipidated polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 44, wherein the second non-pyruvylated non-lipidated polypeptide lacks cysteine at the N-terminus of SEQ ID NO: 44 and does not exhibit a mass shift of +70 Da compared to the corresponding wild-type non-lipidated polypeptide as measured by mass spectrometry.